Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The user experienced significant hair regrowth using 1mg finasteride daily and 5% minoxidil twice a day over 6.5 months, improving from a Norwood 3.5 to a Norwood 2. Despite progress, they still feel their hair is thin, especially at the temples.

User has hair loss, finasteride for 5 years not effective. Considers trying dutasteride, minoxidil, or pyrilutamide.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

A 23-year-old with high estrogen levels is considering starting finasteride for hair loss and plans to use a low dose topical treatment while also seeking to lower estrogen levels. They will consult an endocrinologist for further guidance.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

Switching from finasteride to dutasteride as a treatment for hair loss, and discussing possible side effects or results of the switch.

The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

User visited derma doctor, suggested finasteride, minoxidil, multivitamins, and PRP therapy. Another user advised against PRP due to cost and ineffectiveness.

Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

Some users experienced erectile dysfunction with finasteride but not with dutasteride, while others had issues with both. Individual reactions vary, with some reporting improved mood and hair growth on dutasteride.

The user switched to dutasteride and saw palmetto, along with a topical mix of minoxidil and finasteride, due to continued hair shedding. They hope for improvement despite concerns about saw palmetto's effectiveness.

The conversation is about using RF microneedling with ExoHealer, along with finasteride and minoxidil, to improve hair thickness and reduce shedding. The user reports noticeable improvements in scalp texture and oiliness, with plans to consider stem cell treatments in the future.